StockData
Enanta Pharmaceuticals Inc logo

Enanta Pharmaceuticals Inc (ENTA) income statement

ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 2/302% above fair value
$8.23−0.46 (-5.29%)

Close on Nov 18, 2026Market cap $239.70MP/E –Yield –

Enanta Pharmaceuticals Inc income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-99.0%
Net margin
-108.3%
Return on equity, FY2026
-94.2%

Financial strength

Current ratio
3.78
Debt to equity
–
Debt to assets
–
Cash to current liabilities
37.2%

Valuation

P/E ratio
–
Price to sales
3.80
Price to book
2.99
Dividend yield
–

See a number that looks wrong?